We are live on ! Find out more
SABS icon

SAB Biotherapeutics
SABS

38 hedge funds and large institutions have $2.42M invested in SAB Biotherapeutics in 2022 Q4 according to their latest regulatory filings, with 8 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

311% more capital inflows, than outflows

Capital inflows: $1M | Capital outflows: $244K

1.83% more ownership

Funds ownership: 7.69% → 9.51% (+1.8%)

0% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 8

0% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 9

5% less funds holding

Funds holding: 40 → 38 (-2)

Holders
38
Holders Change
-2
Holders Change %
-5%
% of All Funds
0.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
9
Reduced
9
Closed
8
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Veritable
Veritable
Delaware
+$423K
2
WAM
Warberg Asset Management
Illinois
+$338K
3
HighTower Advisors
HighTower Advisors
Illinois
+$69.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$63.1K
5
Silver Oak Securities
Silver Oak Securities
Tennessee
+$47.5K

Top Sellers

Rank Fund Capital Flow
1
Meteora Capital
Meteora Capital
Florida
-$105K
2
Shaolin Capital Management
Shaolin Capital Management
Florida
-$35.1K
3
Millennium Management
Millennium Management
New York
-$27K
4
Jane Street
Jane Street
New York
-$17K
5
BlackRock
BlackRock
New York
-$16.1K

SABS Hedge Fund Activity: Q4 2022 in Review

38 of the 6,243 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics (SABS) for Q4 2022, worth a combined $2.42M — up 4.2% from $2.32M a quarter earlier.

Fund positioning in SABS was balanced in Q4 2022: 8 funds opened new positions, 8 closed out, 9 added to existing stakes and 9 trimmed.

The largest buyer was Veritable, adding an estimated $423K. The largest seller was Meteora Capital, cutting an estimated $105K.

  • 38 institutional investors held SAB Biotherapeutics (SABS) as of Q4 2022, down from 40 in Q3 2022.
  • Funds reported $2.42M of SAB Biotherapeutics stock for Q4 2022, up 4.2% quarter-over-quarter.
  • 8 funds opened new SAB Biotherapeutics positions in Q4 2022 and 8 closed out, a net change of 0 holders.
  • The largest SAB Biotherapeutics buyer in Q4 2022 was Veritable, an estimated $423K added.
  • The largest SAB Biotherapeutics seller in Q4 2022 was Meteora Capital, an estimated $105K sold.

Based on aggregated 13F filings for Q4 2022.